Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with more than 40 targeted drugs approved, but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.) dominate the field, but many are facing near-term patent expiry. Subcutaneous formulations of these agents offer not only convenience advantages but also an extension to the lifecycle of the drug. Therapeutics addressing driver mutations such as EGFR and ALK also play a crucial role in the NSCLC market, which is significantly biomarker-segmented. These segments will see increasingly fierce competition, especially in the first-line metastatic setting, where the interplay of efficacy and tolerability attributes will influence market share. Expected new market entrants will further drive dynamism in the NSCLC market.
Questions answered
- How will the recent and expected new market entrants shape treatment algorithms in the various settings and stages (I-IV) of NSCLC?
- Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?
- What are the most promising pipeline products, and what will be their likely uptake and patient share in NSCLC?
- What are the NSCLC therapy market’s key drivers and constraints, and how will the market evolve over the forecast period?
Content highlights
- Geographies: United States, France, germany, Italy, Spain, United Kingdom, Japan.
- Primary research: Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research.
- Epidemiology: Diagnosed incidence of NSCLC by country, histology, stage, and line of therapy, segmented into relevant drug-treatable populations.
- Forecast: 10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2035, segmented by brands / generics and epidemiological subpopulations
- Drug treatments: Coverage of key current and late-phase emerging therapies.
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events
Table of contents
- Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Current Treatment
- Key takeaways
- Treatment for NSCLC
- Early-stage (stage I-III) NSCLC
- Metastatic NSCLC
- Treatment decision tree for early-stage (stage I-III) NSCLC
- Treatment decision tree for metastatic (stage IV) NSCLC with EGFR, ALK, BRAF V600E, ROS1, RET, MET exon 14 skipping, or HER2 alterations
- Treatment decision tree for metastatic (stage IV) NSCLC with KRAS G12C or NRG1 alterations, or without actionable mutations
- Key current therapies
- Key takeaways
- Emerging Therapies
- Key takeaways
- Key emerging therapies
- PD-(L)1-targeting antibodies
- PD-(L)1 x CTLA-4-targeting antibodies
- PD-(L)1 x VEGF-targeting antibodies
- TIGIT-targeting antibodies
- LAG-3-targeting antibodies
- CD73-targeting antibodies
- NKG2A-targeting antibodies
- EGFR-targeting agents
- ALK inhibitors
- MET inhibitors
- MET-targeting ADCs
- KRAS G12C inhibitors
- KRAS G12D-targeting degraders
- RAS inhibitors
- PRMT5 inhibitors
- TROP2-targeting ADCs
- Integrin beta-6-targeting ADCs
- PD-L1-targeting ADCs
- Immunomodulating agents
- Viral therapies
- TLR agonists
- Adoptive cell therapies
- Therapeutic vaccines
- PARP inhibitors
- Unmet need
- Key takeaways
- Drug Pipeline
- Appendix
- Executive Summary
